Table 2.
New onset and relapses cases of ANCA-associated glomerulonephritis and other glomerular lesions with ANCA-positive association reported after COVID-19 vaccination.
| Cases of renal involvement reported after COVID-19 vaccination | Total number of cases reported | Type of vaccine | Number of Cases per dose |
|---|---|---|---|
| ANCA-associated Glomerulonephritisa | 31* | mRNA Vaccine - 17 Viral Vector Vaccine - 10 Inactivated Vaccine - 4 |
1st dose: 9 2nd dose: 19 3nd dose: 3 |
| Lupus Nephritis (2* cases ANCA-positive)b | 6* | mRNA Vaccine - 3 Viral Vector Vaccine - 3 |
1st dose: 4 2nd dose: 2 |
| IgA Nephropathy (3 cases ANCA-positive)c |
30 | mRNA Vaccine - 28 Viral Vector Vaccine - 1 Inactivated Vaccine - 1 |
1st dose: 5 2nd dose: 25 |
| Anti-glomerular basement membrane nephritis (6 cases ANCA-positive)d | 14 | mRNA Vaccine - 13 Viral Vector Vaccine - 1 |
1st dose: 5 2nd dose: 8 3nd dose: 1 |
| Crescentic glomerulonephritis (6 cases ANCA-positive)e | 7 | mRNA Vaccine - 7 | 1st dose: 1 2nd dose: 6 |
| Membranous nephropathy (1 case ANCA-positive)f | 7 | mRNA Vaccine - 6 Viral Vector Vaccine - 1 |
1nd dose: 2 2nd dose: 5 |
| Other non-ANCa-positive glomerular lesions | |||
| Minimal change diseaseg | 22 | mRNA Vaccine - 20 Viral Vector Vaccine - 2 |
1st dose: 6 2nd dose: 8 |
| Collapsing glomerulopathyh | 4 | mRNA Vaccine - 2 Viral Vector Vaccine - 2 |
1st dose: 2 2nd dose: 2 |